Experts Say New Name Better Reflects the Condition’s Complexity and Could Reduce Misdiagnosis
A major change has been announced in women’s health as polycystic ovary syndrome (PCOS) has officially been renamed polyendocrine metabolic ovarian syndrome (PMOS) — a move experts believe will improve diagnosis, treatment, and awareness of the condition affecting nearly 1 in 8 women worldwide.
The name change was published in the medical journal The Lancet after 14 years of collaboration between doctors, researchers, and patients. Health experts say the former name, PCOS, often created confusion by focusing only on ovarian cysts, despite the condition involving far more complex hormonal and metabolic issues.
According to the Endocrine Society, the old terminology contributed to missed diagnoses and inadequate care because many patients with the condition do not actually develop ovarian cysts.
Dr. Melanie Cree, a pediatric endocrinology specialist at the University of Colorado Anschutz and one of the contributors to the report, explained that the new name provides a more accurate representation of the disorder.
PMOS is a hormonal and metabolic condition linked to irregular menstrual cycles, excess androgen hormones, acne, abnormal hair growth or thinning, fertility challenges, weight gain, insulin resistance, and increased risks of Type 2 diabetes, heart disease, and stroke.
Medical experts say symptoms can vary widely, making diagnosis difficult. In teenagers, diagnosis typically requires irregular periods alongside signs of elevated androgen levels, such as severe acne or unusual hair growth.
The condition is also considered one of the leading causes of female infertility because irregular ovulation can affect conception. However, specialists stress that many women with PMOS can still successfully carry pregnancies with proper treatment and care.
Doctors say treatment often begins with lifestyle adjustments, including healthier eating habits, regular exercise, and improved sleep patterns. Other treatment options may include insulin-regulating medications like Metformin, hormone therapies, and fertility-focused treatments depending on individual needs.
Healthcare professionals hope the rebranding from PCOS to PMOS will encourage broader understanding of the condition and lead to more personalized and effective patient care worldwide.
